Swing Therapeutics has announced positive results from its Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for fibromyalgia.

The digital therapy is a self-guided smartphone-based behavioral therapy designed to address fibromyalgia symptoms in adult patients. The therapy utilizes acceptance and commitment therapy (ACT), which is a form of cognitive behavioral therapy (CBT) known for its efficacy in treating various chronic pain conditions, including fibromyalgia.

Acceptance and commitment therapy (ACT) typically focuses on helping individuals accept their thoughts and feelings rather than fighting against them, promoting psychological flexibility. In the context of fibromyalgia, this may involve accepting the presence of pain and other symptoms while encouraging patients to commit to actions that align with their values and improve their overall well-being.

Stanza, being a digital therapeutic, allows patients to access and engage with the therapy through their smartphones. The self-guided nature of the program implies that individuals can progress through the therapy at their own pace, providing a level of flexibility that may be particularly beneficial for those managing chronic conditions like fibromyalgia.

The digital therapy likely includes various modules or components aimed at addressing specific aspects of fibromyalgia, such as pain intensity, fatigue, sleep disturbance, depression, and physical function. The positive results from the PROSPER-FM trial suggest that Stanza has demonstrated significant clinical benefits, offering improvements in overall well-being, fibromyalgia severity, and major symptoms associated with the condition.

The trial, presented at the ACR 2023 annual meeting, involved 275 participants and demonstrated Stanza’s efficacy in improving patient outcomes. Stanza, granted De Novo marketing authorization by the FDA in May 2023, is the first prescription digital therapeutic for treating fibromyalgia symptoms.

Article written by Jenna Kane